University of Southern California
USC Norris Comprehensive Cancer Center


Not logged in...


If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-17-6


Phase 1b/II Study of Escalating Doses of Pevonedistat (Tak-924, Formerly Mln4924) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Kevin Kelly, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Ashot Minasyan, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.